CGIM
ALNY icon

Capital Group Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital Group Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95M Hold
6,474
– – 0.29% 80
2026
Q1 		$2.14M Sell
6,474
-8,372
-56% -$2.85M 0.37% 74
2025
Q4 		$5.9M Sell
14,846
-2,017
-12% -$893K 0.96% 28
2025
Q3 		$7.69M Sell
16,863
-875
-5% -$356K 1.29% 18
2025
Q2 		$5.78M Buy
17,738
+388
+2% +$107K 1.03% 25
2025
Q1 		$4.68M Buy
17,350
+179
+1% +$46K 0.96% 31
2024
Q4 		$4.04M Sell
17,171
-4,176
-20% -$1.1M 0.77% 35
2024
Q3 		$5.87M Buy
21,347
+1,777
+9% +$463K 1.18% 23
2024
Q2 		$4.76M Buy
19,570
+3,397
+21% +$536K 1.03% 27
2024
Q1 		$2.42M Sell
16,173
-16,251
-50% -$2.71M 0.43% 69
2023
Q4 		$6.21M Sell
32,424
-21,092
-39% -$3.59M 0.65% 48
2023
Q3 		$9.48M Buy
53,516
+34,048
+175% +$6.5M 0.62% 68
2023
Q2 		$3.7M Hold
19,468
– – 0.18% 96
2023
Q1 		$3.9M Sell
19,468
-2,582
-12% -$543K 0.21% 96
2022
Q4 		$5.24M Buy
+22,050
New +$4.7M 0.2% 90

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Group Investment Management's ALNY Position: Q2 2026 in Review

Capital Group Investment Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 6,474 shares worth $1.95M. The position accounts for 0.29% of the portfolio, ranked #80.

Capital Group Investment Management first reported a position in ALNY in Q4 2022 and has held it in 15 quarters since. The position peaked at $9.48M in Q3 2023. 792 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Capital Group Investment Management held 6,474 shares of Alnylam Pharmaceuticals worth $1.95M as of Q2 2026.
  • Capital Group Investment Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.29% of Capital Group Investment Management's portfolio in Q2 2026, its #80 holding.
  • Capital Group Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Capital Group Investment Management's Alnylam Pharmaceuticals position peaked at $9.48M in Q3 2023.
  • 792 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Capital Group Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.